DMAC SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

DiaMedica Therapeutics Reports Q2 2026 Financial Results and Clinical Progress for DM199

Aug 10, 2026

8-K

DiaMedica Therapeutics Inc. Announces Results of 2026 Annual General Meeting of Shareholders

May 21, 2026

8-K

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 6, 2026

8-K

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Business Highlights

Mar 30, 2026

8-K

DiaMedica Therapeutics Inc. Completes Common Share Sale

Jan 5, 2026

8-K

DiaMedica Therapeutics Updates on DM199 Preeclampsia Program Following FDA Pre-IND Meeting

Dec 18, 2025

Prospectus

TYPE

HEADLINE

FILED AT

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Aug 22, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 4,720,000 | Share price: $2.50

Jul 18, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 11,011,406 | Share price: $3.40

Jul 10, 2023

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 7,653,060 | Share price: $3.92

Oct 15, 2021

424B5

SHELF OFFERING | Shares amount: 4,000,000 | Share price: $5.00 | Offering amount: $20,000,000.00 | Bank: Guggenheim Securities

Aug 7, 2020

424B5

PENDING OFFERING

Aug 5, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 11, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 13, 2025

S-3

August 2025 SHELF

Aug 12, 2025

S-3

SHARE RESALE REGISTRATION

Aug 1, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Jul 24, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 4,720,000 | Share price: $2.50 EFFECTIVE

Jul 10, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 1, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 1, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 4, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 4, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Pauls Dietrich John (Reporting)

Aug 12, 2026

Giuffre Randall Michael (Reporting)

Jun 3, 2026

Kuntz Richard (Reporting)

Jun 3, 2026

O'Connor Daniel J. (Reporting)

Jun 3, 2026

Lewis Tanya (Reporting)

Jun 3, 2026

Semba Charles Pauling (Reporting)

Jun 3, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 25, 2025

CORRESP

Form CORRESP - Correspondence

Aug 20, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 18, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 11, 2025

CORRESP

Form CORRESP - Correspondence

Aug 6, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 5, 2025

DiaMedica Therapeutics Inc. DMAC · SEC Filings